AU2221600A - Improved expression of hiv polypeptides and production of virus-like particles - Google Patents

Improved expression of hiv polypeptides and production of virus-like particles

Info

Publication number
AU2221600A
AU2221600A AU22216/00A AU2221600A AU2221600A AU 2221600 A AU2221600 A AU 2221600A AU 22216/00 A AU22216/00 A AU 22216/00A AU 2221600 A AU2221600 A AU 2221600A AU 2221600 A AU2221600 A AU 2221600A
Authority
AU
Australia
Prior art keywords
virus
particles
production
improved expression
hiv polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22216/00A
Other languages
English (en)
Inventor
Susan Barnett
Catherine Greer
Karin Hartog
Ying Lian
Hong Liu
Mark Selby
Indresh Srivastava
Christopher Walker
Jan Zur Megede
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2221600A publication Critical patent/AU2221600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU22216/00A 1998-12-31 1999-12-30 Improved expression of hiv polypeptides and production of virus-like particles Abandoned AU2221600A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11449598P 1998-12-31 1998-12-31
US60114495 1998-12-31
US16847199P 1999-12-01 1999-12-01
US60168471 1999-12-01
PCT/US1999/031245 WO2000039302A2 (en) 1998-12-31 1999-12-30 Improved expression of hiv polypeptides and production of virus-like particles

Publications (1)

Publication Number Publication Date
AU2221600A true AU2221600A (en) 2000-07-31

Family

ID=26812261

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22216/00A Abandoned AU2221600A (en) 1998-12-31 1999-12-30 Improved expression of hiv polypeptides and production of virus-like particles

Country Status (6)

Country Link
US (5) US6602705B1 (enExample)
EP (3) EP1980617A1 (enExample)
JP (3) JP2002533124A (enExample)
AU (1) AU2221600A (enExample)
CA (1) CA2360347C (enExample)
WO (1) WO2000039302A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784635B2 (en) * 1999-11-16 2006-05-18 Geneart Ag The genome of the HIV-1 inter-subtype (C/B') and use thereof
AU785283B2 (en) * 1999-12-14 2006-12-21 Uab Research Foundation, The Fusion protein delivery system and uses thereof

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173643A1 (en) * 1995-04-14 2002-11-21 Kappes John C. Fusion protein delivery system and uses thereof
EP0935659A1 (en) 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2003523721A (ja) * 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000065076A2 (en) * 1999-04-26 2000-11-02 K.U. Leuven Research & Development Synthetic gene for expressing active retroviral protein in eukaryotes
DE60024442T2 (de) * 1999-06-11 2006-08-03 MediGene, Inc., San Diego Verwendung von viralen vektoren und geladenen molekülen für die gentherapie
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
ATE438714T1 (de) * 1999-12-23 2009-08-15 Us Gov Health & Human Serv Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
KR100854917B1 (ko) 2000-03-30 2008-08-27 가부시키가이샤 디나벡크 겐큐쇼 센다이바이러스 벡터를 사용한 ａｉｄｓ 바이러스 백신
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002012454A1 (en) * 2000-08-08 2002-02-14 The Kitasato Institute Virus-like micrograins and process for producing the same
EP1311686A2 (en) * 2000-08-14 2003-05-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
WO2002022080A2 (en) * 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
EP1322287B1 (en) * 2000-09-28 2006-03-22 Chiron Corporation Microparticles for delivery of the heterologous nucleic acids
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
WO2002042326A1 (en) * 2000-11-22 2002-05-30 Biota Scientific Management Pty Ltd A method of expression and agents identified thereby
WO2002080982A2 (en) 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
JP2004537279A (ja) * 2001-03-09 2004-12-16 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 感染性ｃ型肝炎ウイルス合成のための細胞培養システム
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
WO2002094994A2 (en) * 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
ES2356934T3 (es) * 2001-06-05 2011-04-14 Curevac Gmbh ARNm ESTABILIZADO CON UN CONTENIDO DE G/C AUMENTADO QUE CODIFICA PARA UN ANTÍGENO VIRAL.
US20030198621A1 (en) 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
AU2002320314A1 (en) * 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1427806A4 (en) * 2001-08-31 2006-04-26 Chiron Corp ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
CA2459426A1 (en) * 2001-09-06 2003-03-20 Progenics Pharmaceuticals, Inc. Human immunodeficiency virus envelope glycoprotein mutants and uses thereof
JP4601956B2 (ja) * 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
AU2003215193A1 (en) * 2002-02-11 2003-09-04 Joseph D. Mosca Production of a protein delivery system for in vivo therapeutic treatment
WO2003072750A2 (en) * 2002-02-27 2003-09-04 Prodigene, Inc. Expression of hiv-related proteins in plants
WO2003087757A2 (en) * 2002-04-05 2003-10-23 Progenics Pharmaceuticals, Inc. Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
EP1553976B1 (en) 2002-05-07 2013-08-21 Novartis Vaccines and Diagnostics, Inc. Hiv envelope-cd4 complexes and hybrids
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
EP1546329A4 (en) * 2002-09-13 2006-07-12 Univ Queensland CODONTRANSLATION EFFICIENCY BASED GENE EXPRESSION SYSTEM
AU2003282498A1 (en) 2002-10-07 2004-05-04 Chiron Corporation Hiv vaccine formulations
WO2004043376A2 (en) * 2002-11-07 2004-05-27 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
WO2004046168A2 (en) * 2002-11-15 2004-06-03 The Henry M. Jackson Foundation Recombinant hiv-1 subclass d envelope glycoproteins
CN1745095A (zh) * 2002-12-04 2006-03-08 开普敦大学 一种生产hiv－1的gag病毒样颗粒的方法
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
EP1614096A1 (en) * 2003-04-07 2006-01-11 Koninklijke Philips Electronics N.V. Display device
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US20050031639A1 (en) * 2003-05-12 2005-02-10 Yamamoto Janet K. Materials and methods for immunizing against FIV infection
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
US20070073048A1 (en) * 2003-05-15 2007-03-29 Ying Lian Hiv polynucleotides and polypeptides derived from botswana mj4
US7419674B2 (en) 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
WO2005011571A2 (en) 2003-07-30 2005-02-10 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CA2539021A1 (en) * 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
WO2005062871A2 (en) * 2003-12-19 2005-07-14 University Of Maryland Biotechnology Institute Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
EP1784513A4 (en) 2004-06-08 2010-01-06 Novartis Vaccines & Diagnostic FUSION PROTEINS WITH CD4 MINIMUM MODULES AND USE METHOD THEREFOR
WO2006002079A2 (en) * 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
EP1814583A2 (en) 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
CA2597040A1 (en) 2005-02-03 2006-08-10 Novartis Vaccines And Diagnostics, Inc. Hiv tat-cd4 hybrid molecules and methods of use thereof
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
EP2025762A3 (en) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex tracking assay
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
EP2040747A4 (en) * 2006-06-19 2010-08-25 Progenics Pharm Inc SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE
EP2041321A4 (en) 2006-07-13 2009-12-23 Inst Advanced Study VIRAL INHIBITORY NUCLEOTIDE SEQUENCES AND VACCINES
US9439959B2 (en) * 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
CA2679511A1 (en) * 2007-03-16 2008-09-25 454 Life Sciences Corporation System and method for detection of hiv drug resistant variants
JP5602624B2 (ja) 2007-06-21 2014-10-08 アルファバックス， インコーポレイテッド αウイルス構造タンパク質の発現のためのプロモーターレスカセット
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducción de respuestas inmunes
GB0802224D0 (en) * 2008-02-06 2008-03-12 Inst Superiore Di Sanito Process for the production of vaccine components
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
US20120121633A1 (en) * 2010-07-16 2012-05-17 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
PT3981427T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
TR201903651T4 (tr) * 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
WO2012061146A1 (en) 2010-10-25 2012-05-10 The Children's Hospital Of Philadelphia Compositions and methods for the generation of platelets and methods of use thereof
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US10150970B2 (en) 2011-07-27 2018-12-11 Applied Biotechnology Institute, Inc. Methods to increase antigenicity of membrane-bound polypeptides produced in plants
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2780035A1 (en) 2011-11-14 2014-09-24 Novartis AG Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof
DK2790737T3 (en) * 2011-12-12 2019-03-18 Childrens Hospital Philadelphia COMMERCIAL LARGE SCALE LENTIVIRUS VECTOR-MANUFACTURING SYSTEM AND VECTORS MADE THEREOF
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
AU2015236147A1 (en) * 2014-03-25 2016-10-13 Duke University Mosaic HIV-1 sequences and uses thereof
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
US9834583B2 (en) 2015-03-16 2017-12-05 The Catholic University Of America Authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
WO2018055535A2 (en) 2016-09-21 2018-03-29 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
US12357034B2 (en) 2018-03-19 2025-07-15 Tsung-Yu Pan Non-igniting, non-electric cigarette simulator that eliminates nicotine from user's body
AU2019368218A1 (en) 2018-10-22 2021-05-27 New York University Recombinant GP120 protein with V1-loop deletion
US20220194990A1 (en) * 2019-01-31 2022-06-23 Board Of Regents Of The University Of Nebraska Virus-like particles and methods of use thereof
WO2025133250A1 (en) * 2023-12-21 2025-06-26 Universitat Pompeu Fabra Pseudotyped viral like particle for immune cells transduction

Family Cites Families (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4738927A (en) 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
ATE220101T1 (de) 1983-04-25 2002-07-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinähnlichen wachstumsfaktoren
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
WO1985002862A1 (en) 1983-12-23 1985-07-04 Monash University PRODUCTION OF HUMAN INTERFERON-alpha
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US5464774A (en) 1984-03-05 1995-11-07 The Salk Institute For Biological Studies Bovine basic fibroblast growth factor
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US7815916B1 (en) 1984-08-22 2010-10-19 The United States Of America As Represented By The Secretary Of Health And Human Services Cloning and expression of HTLV-III DNA
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
WO1986003224A1 (en) 1984-11-29 1986-06-05 Scripps Clinic And Research Foundation Polypeptides and antibodies related to deglycosylated viral glycoproteins
EP0187041B1 (en) 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
NZ215867A (en) 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
ATE108022T1 (de) 1985-10-24 1994-07-15 Southwest Found Biomed Res Synthetische peptide und deren verwendung zur diagnose und impfung für aids und arc.
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
EP0242216A1 (en) 1986-04-16 1987-10-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4879227A (en) 1986-05-06 1989-11-07 Genetics Institute, Inc. Production of a recombinant human colony stimulating factor
CA1338800C (en) 1986-06-17 1996-12-17 Michael Houghton Hepatitis delta and diagnostics and vaccines
AU7786387A (en) 1986-07-21 1988-02-10 Southwest Foundation For Biomedical Research Composition of matter and method of immunizing against viral causative agents of aids and arc
US5135855A (en) 1986-09-03 1992-08-04 The United States Of America As Represented By The Department Of Health And Human Services Rapid, versatile and simple system for expressing genes in eukaryotic cells
US4861707A (en) 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
ES2167304T3 (es) 1987-06-22 2002-05-16 Medeva Holdings Bv Peptido que contiene el antigeno de superficie de la hepatitis b.
WO1989001940A1 (en) 1987-09-04 1989-03-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
DE10399031I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989002277A2 (en) 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US5879907A (en) 1987-09-14 1999-03-09 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof and method
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
JPH03504079A (ja) 1988-03-21 1991-09-12 カイロン　コーポレイション 組換えレトロウィルス
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1340748C (en) 1988-07-13 1999-09-14 Stephen Oroszlan Synthetic hiv protease gene and method for its expression
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
DE68918867T2 (de) 1988-09-13 1995-02-16 Chiron Corp Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
KR900701836A (ko) 1988-10-03 1990-12-04 라메쉬 엘. 라탄 신규 hiv 단백질 및 aids의 진단, 예방 또는 치료에 유용한 펩티드
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
CA2003383A1 (en) 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
JPH04503301A (ja) 1988-12-01 1992-06-18 ザ　トラスティーズ　オブ　ザ　ユニバーシティ　オブ　ノース　カロライナ 合成インターロイキン―６
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL93682A (en) 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
WO1990011359A1 (en) 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
CA2357538A1 (en) 1989-03-21 1990-10-04 Wisconsin Alumni Research Foundation Expression of exogenous polynucleotide sequences in a vertebrate
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU5421090A (en) 1989-04-05 1990-11-05 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A clone of double-stranded rna virus and applications thereof
US5691170A (en) * 1989-04-18 1997-11-25 Therion Biologics Generation of hybrid genes and proteins by virus-mediated recombination
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
ES2198400T3 (es) 1989-06-01 2004-02-01 Applied Biotechnology, Inc. Vector que codifica particulas virales no autopropagantes, defectuosas, auto-ensambladas.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5130247A (en) 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
AU6523590A (en) 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
EP0424748B1 (en) 1989-10-23 1995-05-10 F. Hoffmann-La Roche Ag Synthetic envelope peptides of HTLV-I
WO1991006319A1 (en) 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
AU6965591A (en) 1989-11-17 1991-06-13 Amgen, Inc. A method of detecting htlv-i antibodies in human body fluids
HUT60506A (en) 1989-11-20 1992-09-28 Oncogen Process for producing non-replicable, recombinant retrovirus particles and antiviral and immunogenic preparations
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
ATE207930T1 (de) 1990-03-09 2001-11-15 Chiron Corp Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt
US5876724A (en) 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
ATE183235T1 (de) 1990-03-21 1999-08-15 Wolf Hans Joachim Prof Dr Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
EP0527760B1 (en) 1990-04-03 1995-07-19 Genentech, Inc. Methods and compositions for vaccination against hiv
JPH05506221A (ja) 1990-04-03 1993-09-16 ジェネンテク，インコーポレイテッド Ｈｉｖエンベロープポリペプチド
IL97985A0 (en) 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
WO1992001800A1 (en) 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
SE470074B (sv) 1990-08-16 1993-11-01 Replico Medical Ab Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider
EP0551308A4 (en) 1990-08-29 1994-09-14 Us Health Novel peptide antigens and immunoassays, test kits and vaccines using the same
GB9021004D0 (en) 1990-09-27 1990-11-07 Wellcome Found Acellular vaccines
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0550516A1 (en) 1990-09-28 1993-07-14 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
IE920366A1 (en) 1991-02-04 1992-08-12 Univ Saskatchewan Vp6 encapsulated drug delivery
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
CA2104958A1 (en) 1991-03-07 1992-09-08 Jean C. Nichols Use of cell surface receptor targeted molecules for the treatment of viral diseases
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993002102A1 (en) 1991-07-23 1993-02-04 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Novel peptide antigens and immunoassays, test kits and vaccines using the same
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
EP0554446B1 (en) 1991-08-22 1998-11-04 Nissin Shokuhin Kabushiki Kaisha Monoclonal antibodies useful in therapy of HIV-1 infection
US5558865A (en) 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
EP0608261B1 (en) 1991-09-13 2002-11-27 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
CA2122263A1 (en) 1991-10-28 1993-05-13 Marc Girard Induction of protection against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
AU3483293A (en) 1992-01-22 1993-09-01 New England Medical Center Hospitals, Inc., The Pathogen-specific CTL therapy
US5214804A (en) * 1992-01-27 1993-06-01 Carey Michael J Protective mask with scarf
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
AU3945893A (en) 1992-04-09 1993-11-18 Abbott Laboratories Assay for detection of HIV antigen and HIV antibody
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
PT643585E (pt) 1992-06-01 2000-05-31 Chiron Corp Utilizacao de inibidor da coagulacao associado a lipoproteinas (laci) para a preparacao de um medicamento para o tratamento de inflamacao aguda ou cronica
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
AU4408493A (en) 1992-06-11 1994-01-04 Washington University Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders
AU4798293A (en) 1992-07-27 1994-02-14 New York University High field magnets for medical applications
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US5686078A (en) 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
CA2105629A1 (en) 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ATE233814T1 (de) 1992-09-30 2003-03-15 Scripps Research Inst Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1994016060A1 (en) 1993-01-11 1994-07-21 The Trustees Of The University Of Pennsylvania Mutants of hiv for supression of hiv infection
CA2153778C (en) 1993-01-13 2004-07-06 Arsinur Burcoglu Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
DK0679187T4 (da) 1993-01-16 2001-09-17 Manfred Schawaller Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
US6955900B1 (en) 1993-02-02 2005-10-18 The Scripps Research Institute Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
AU6359794A (en) 1993-03-05 1994-09-26 Genelabs Technologies, Inc. Method for hiv quantitation
EP0689455A4 (en) 1993-03-11 1997-07-23 Univ Southern California THERAPEUTIC STRATEGIES FOR THE TREATMENT OF IMMUNO-INFECTIOUS GROUP VIRAL INFECTIONS
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
AU686616B2 (en) 1993-03-26 1998-02-12 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US5591601A (en) 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5864027A (en) 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
BR9406821A (pt) 1993-06-09 1996-03-26 Connaught Lab Peptideo sintético composiçao imunogenica kit de diagnostico útil para dectar anticorpos especificos de hiv em amostra de teste kit de diagnostico para detectar antigenos de hiv em amostra de teste codificaçao de molécula de ácido nucléico e anticorpo
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
JPH09501562A (ja) 1993-07-19 1997-02-18 ジェン−プローブ・インコーポレイテッド ヒト・免疫不全ウイルスに対する活性を有するオリゴヌクレオチド
WO1995004818A1 (en) 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
JPH0786988A (ja) * 1993-09-16 1995-03-31 Fujitsu Ltd Ｐｃａ伝送装置及びｐｃａ伝送方法
EP0724651B1 (en) 1993-10-19 2008-08-20 The Scripps Research Institute Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2169453A1 (en) 1993-10-26 1995-05-04 Cecil Czerkinsky Inhibition of hiv mucosal infection
WO1995013376A1 (en) 1993-11-10 1995-05-18 Amgen Inc. Gene therapy vector for the treatment of low or defective red blood cell production
IL112820A0 (en) 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
EP0750636A1 (en) 1994-03-14 1997-01-02 University Of Southern California Methods to diagnose and treat hiv-1 infection
CA2188675A1 (en) 1994-04-11 1995-10-19 Savio L. C. Woo Compositions and methods for gene therapy to treat disease
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
ES2177648T3 (es) 1994-04-29 2002-12-16 Univ Duke Vacuna sintetica para proteccion frente a infeccion por virus de inmunodeficiencia humana.
EP0763204A1 (en) 1994-05-31 1997-03-19 Abbott Laboratories Detection of different hiv genotypes utilizing a synthetic peptide-modified immunoassay
AU2656295A (en) 1994-06-02 1996-01-04 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
US5733781A (en) 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US5955342A (en) 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US5648331A (en) 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
WO1996009066A2 (en) 1994-09-23 1996-03-28 The Johns Hopkins University School Of Medicine Method of treatment of human immunodeficiency virus (hiv) infection
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
CA2205130A1 (en) 1994-11-17 1996-05-30 Jan Roland Holmgren Immunogens for stimulating mucosal immunity
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5550280A (en) 1994-11-30 1996-08-27 Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee Hindered aromatic ester compounds useful as anti-viral agents
WO1996021015A2 (en) 1994-12-30 1996-07-11 Chiron Corporation Combination gene delivery vehicles
WO1996020732A2 (en) 1994-12-30 1996-07-11 Chiron Corporation Non-traumatic administration of gene delivery vehicles
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
FR2730411B1 (fr) 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
AU6483896A (en) 1995-07-07 1997-02-10 The Texas A & M University System Nucleotide and amino acid sequence and uses thereof
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6456096A (en) 1995-07-11 1997-02-10 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
NZ319891A (en) 1995-09-28 1999-01-28 Univ Pittsburgh Stimulation of cytotoxic t lymphocyte response to tumour or virus by targeted particulate polynucleotide genetic immunisation
US5766464A (en) * 1995-11-22 1998-06-16 Campbell; David C. Fluid filtration system positionable within a fluid-containing apparatus
WO1997026009A1 (en) 1996-01-17 1997-07-24 Progenics Pharmaceuticals, Inc. Compounds capable of inhibiting hiv-1 infection
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6087486A (en) 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
US6060587A (en) 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
IL125547A0 (en) * 1996-02-22 1999-03-12 Merck & Co Inc Synthetic hiv genes
ES2301178T3 (es) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
AU728422B2 (en) 1996-06-21 2001-01-11 Merck & Co., Inc. Vaccines comprising synthetic genes
US5951975A (en) 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
AU4088697A (en) 1996-08-26 1998-03-19 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
US6093800A (en) 1996-09-06 2000-07-25 The Regents Of The University Of California E25a protein, methods for production and use thereof
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6139833A (en) 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
CN1252075A (zh) * 1997-02-07 2000-05-03 麦克公司 合成的hiv gag基因
ID24565A (id) 1997-03-14 2000-07-27 Idec Pharma Corp Metoda untuk integrasi gen pada tempat yang spesifik dalam sel mamalia melalui rekombinasi homolog dan vektor untuk pencapaian yang sama
AU6535898A (en) 1997-03-14 1998-10-12 President And Fellows Of Harvard College Glycosylation deficient siv and hiv envelope glycoproteins
EP0968477A1 (en) 1997-03-24 2000-01-05 Queen's University At Kingston Coincidence detection method, products and apparatus
CA2259041A1 (en) 1997-04-28 1998-11-05 Arsinur Burcoglu Method of treating hiv infection and related secondary infections thereof
US5858675A (en) 1997-05-13 1999-01-12 Incyte Pharmaceuticals, Inc. Double-stranded RNA-binding protein
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
AU8160298A (en) 1997-06-23 1999-01-04 Emory University Human immunodeficiency viruses causing aids in a nonhuman primate
CA2296067C (en) 1997-07-09 2008-10-07 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
JP4166940B2 (ja) 1997-08-01 2008-10-15 バイオ−ラッド ラボラトリーズ，インコーポレイティド Ｈｉｖウイルスに対して免疫反応性である抗体の検出用の合成抗原
AU9310298A (en) 1997-09-09 1999-03-29 Trustees Of Columbia University In The City Of New York, The T-independent conjugate-vaccines
EP1028712B1 (en) 1997-09-19 2005-01-12 Shire Laboratories Inc. Solid solution beadlet
US5932442A (en) 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
EP1019511A2 (en) 1997-10-01 2000-07-19 Dana-Farber Cancer Institute STABILIZATION OF ENVELOPE GLYCOPROTEIN TRIMERS BY DISULFIDE BONDS INTRODUCED INTO A gp41 GLYCOPROTEIN ECTODOMAIN
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
CA2320513A1 (en) 1998-02-11 1999-08-19 Joseph T. Bruder Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
JP2002511396A (ja) 1998-04-14 2002-04-16 メルク エンド カムパニー インコーポレーテッド ポリヌクレオチド製剤の無針投与
EP1078052A2 (en) 1998-04-14 2001-02-28 Chiron Corporation Noncloning technique for expressing a gene of interest
JP2002512013A (ja) 1998-04-22 2002-04-23 カイロン コーポレイション ケモカインを使用することによる遺伝的免疫に対する免疫応答の増強
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
FR2780069B1 (fr) 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
WO2000008043A2 (en) 1998-08-03 2000-02-17 The University Of Montana Prevention and treatment of viral disease
WO2000015819A1 (en) * 1998-09-11 2000-03-23 The Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
WO2000018929A2 (en) 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
AU6425999A (en) 1998-10-09 2000-05-01 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000039303A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Modified hiv env polypeptides
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1147211B1 (en) 1999-01-27 2009-06-17 Stratagene California High level expression of a heterologous protein having rare codons
EP1165798A2 (en) * 1999-03-29 2002-01-02 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
WO2000065076A2 (en) 1999-04-26 2000-11-02 K.U. Leuven Research & Development Synthetic gene for expressing active retroviral protein in eukaryotes
EP1181057B1 (en) 1999-05-03 2012-08-01 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
KR100873157B1 (ko) 1999-05-06 2008-12-10 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
WO2000067787A2 (en) 1999-05-06 2000-11-16 The Immune Response Corporation Hiv immunogenic compositions and methods
US6420545B1 (en) 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE
DE60041335D1 (de) 1999-08-19 2009-02-26 Dynavax Tech Corp Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
EP1214437A1 (en) 1999-08-27 2002-06-19 The Regents of the University of California Use of lentiviral vectors for antigen presentation in dendritic cells
CA2384271A1 (en) 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
WO2001021270A2 (en) 1999-09-21 2001-03-29 Prodigene, Inc. Methods for producing recombinant proteins
JP2003511420A (ja) 1999-10-13 2003-03-25 カイロン コーポレイション タンパク質から細胞性免疫応答を得る方法
EP1226241A1 (en) 1999-10-21 2002-07-31 Panorama Research, Inc. A general method for optimizing the expression of heterologous proteins
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
DE50015096D1 (de) 1999-11-16 2008-05-21 Geneart Ag Das genom des hiv-1 intersubtyps (c/b') und seine anwendungen
AU2841101A (en) 1999-12-08 2001-06-18 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
JP2003516741A (ja) 1999-12-17 2003-05-20 メルク エンド カムパニー インコーポレーテッド コドン最適化ＨＩＶ−１Ｎｅｆ及び修飾ＨＩＶ−１Ｎｅｆを発現するポリヌクレオチドワクチン
EP1242124A4 (en) 1999-12-22 2004-07-14 Merck & Co Inc POLYNUCLEOTIDE VACCINES EXPRESSING CODONE-OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL
CA2392877C (en) 1999-12-23 2011-11-15 Tomas Hanke Improvements in or relating to immune responses to hiv
ATE438714T1 (de) 1999-12-23 2009-08-15 Us Gov Health & Human Serv Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
WO2001054701A1 (en) 2000-01-31 2001-08-02 Aventis Pasteur, S.A. Vaccination of hiv infected persons following highly active antiretroviral therapy
KR20070073987A (ko) 2000-01-31 2007-07-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｉｖ에 대한 예방 또는 치료용 면역화를 위한 백신
WO2001060393A1 (en) 2000-02-16 2001-08-23 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
JP2003523188A (ja) 2000-02-18 2003-08-05 ユニバーシティ・オブ・ワシントン Ａｉｄｓ先祖ウイルスおよびワクチン
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2008086329A2 (en) 2007-01-08 2008-07-17 Continental Automotive Systems Us, Inc. Dc/dc converter
EP2510962A1 (en) 2011-04-12 2012-10-17 F. Hoffmann-La Roche AG Infusion pump device with re-filling scheme for cylinder-piston dosing unit

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784635B2 (en) * 1999-11-16 2006-05-18 Geneart Ag The genome of the HIV-1 inter-subtype (C/B') and use thereof
AU785283B2 (en) * 1999-12-14 2006-12-21 Uab Research Foundation, The Fusion protein delivery system and uses thereof

Also Published As

Publication number Publication date
CA2360347A1 (en) 2000-07-06
WO2000039302A3 (en) 2001-01-04
EP1980617A1 (en) 2008-10-15
JP2002533124A (ja) 2002-10-08
US8168418B2 (en) 2012-05-01
JP2011019534A (ja) 2011-02-03
US20120269840A1 (en) 2012-10-25
US20110065146A1 (en) 2011-03-17
US7718401B2 (en) 2010-05-18
US7348177B2 (en) 2008-03-25
EP1141313A2 (en) 2001-10-10
US6602705B1 (en) 2003-08-05
EP2206785A1 (en) 2010-07-14
CA2360347C (en) 2013-05-07
US20030223964A1 (en) 2003-12-04
JP2011172593A (ja) 2011-09-08
WO2000039302A2 (en) 2000-07-06
US20080261271A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
AU2221600A (en) Improved expression of hiv polypeptides and production of virus-like particles
AU4987700A (en) Polymerized modified particles and methods of making the same
AU2000273206A1 (en) Photocatalyst-bearing material and method of producing the same
AU4065200A (en) Zirconia sol and process of making same
AU1687599A (en) Sm-fe-n alloy powder and process for the production thererof
AU2781199A (en) Pulsed-energy controllers and methods of operation thereof
AU6746800A (en) Carbon-reinforced electrode and method of making same
AU8147898A (en) Recombinant materials and methods for the production of limonene hydroxylases
AU6204398A (en) Cast part, and production of same
AU2460099A (en) Mesoporous materials and methods of making the same
AU4147296A (en) Decorative construction material and methods of its production
AU4218400A (en) Lyophilized solid dosage forms and methods of making
AU6158399A (en) Production of powder formulations
AU4313900A (en) Micromachine switch and method of manufacture thereof
AU2001246339A1 (en) Lyophilized powder of lentinan and the process of preparation thereof
AU7334698A (en) Process for preparing pure flupirtin maleate and its modification
AU7290898A (en) Preparation of fagopyritols and uses therefor
AU9082998A (en) Dry powder aerosol production
AU6373698A (en) Production of L(+)-Lactate
AU4929497A (en) Processing of ceramic materials
AU2002228801A1 (en) Post-crepe stabilized material and method of producing the same
AU6953100A (en) Cftr polypeptides, fragments thereof and methods of use to overcome biosyntheticmisprocessing
AU5504999A (en) Production of proteins
AU1334801A (en) Low density marshmallow-like products and methods of producing the same
AUPP091197A0 (en) Direct manipulation of compressed geometry

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase